Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
5 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (4 thèses dirigées)
Expérience confirmée
34 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
134.8 rhumatos / 100 000 hab. — département bien doté
34ans d'exercice (thèse 1992)
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
✨ Génération du profil synthétique IA en cours…
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Exploitation de données de santé longitudinales : de l'épidémiologie du diabète de type 1 à l'intelligence artificielle pour la prédiction de la rétinopathie diabétique. Le cas de la cohorte CARéDIAB
2024Doctorant·e : Sara Barraud
Médecine de précision du diabète de type 2 et des obésités génétiques
2023Doctorant·e : Lauriane Le Collen
Incidentalomes surrenaliens : une pathologie reconnue depuis 10 ans : evaluation de notre attitude diagnostique en therapeutique actuelle
1994Doctorant·e : MAXIME HUGUIER
Etude du profil longitudinal de lhémoglobine glyquée et de son impact sur les complications chroniques du diabète et sur la qualité de vie dans le diabète de type 1: la cohorte CARéDIAB (Champagne Ardenne Réseau Diabète) .
Doctorant·e : Alpha mamadou Diallo
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
51
51 articles ont été cités au moins 51fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
9 636
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
302
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
120
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre de Recherche en Sciences et Technologies de l'Information et de la Communication · Centre Hospitalier Universitaire de Reims · Hôpital Robert-Debré
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
From misclassified AIP variant to carney complex: a case report and retrospective evaluation of PRKAR1A in pituitary tumor predisposition
2025ArticlePituitary
French expert consensus statement on diagnosis and management of primary hyperparathyroidism
2025ArticleAnnales d'Endocrinologie = Annals of Endocrinology
Biallelic pathogenic variants in POMC can cause combined pituitary hormonal deficiency associated with severe obesity
2025ArticleEuropean Journal of Endocrinology
Tatton-Brown-Rahman syndrome: A new multiple endocrine neoplasia syndrome with intellectual disability?
2025ArticleAnnales d'Endocrinologie = Annals of Endocrinology
Lipodystrophy and severe insulin resistance syndrome: epidemiological data from a French national rare diseases registry
2025ArticleAnnales d'Endocrinologie = Annals of Endocrinology
Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network
2025ArticleDiabetes, Obesity and Metabolism
Rare ZMPSTE24 variants increase risk of hypertriglyceridemia and metabolic syndrome
2025ArticleEuropean Journal of Endocrinology
Parcours des patients avec un diabète de type 1 dans la cohorte CARéDIAB, lien avec la rétinopathie diabétique
2025CongrèsCongrès national de la Société Francophone du Diabète (SFD)
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL ROBERT DEBRE CHU REIMS
R DU GENERAL KOENIG, 51092 REIMS CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Diabetic medicine : a journal of the British Diabetic Association · 2022
AbstractAimsTo update and extend a previous cross‐sectional international comparison of glycaemic control in people with type 1 diabetes.MethodsData were obtained for 520,392 children and adults with type 1 diabetes from 17 population and five clinic‐based data sources in countries or regions between 2016 and 2020. Median HbA1c(IQR) and proportions of individuals with HbA1c < 58 mmol/mol (<7.5%), 58–74 mmol/mol (7.5–8.9%) and ≥75 mmol/mol (≥9.0%) were compared between populations for individuals aged <15, 15–24 and ≥25 years. Logistic regression was used to estimate the odds ratio (OR) of HbA1c < 58 mmol/mol (<7.5%) relative to ≥58 mmol/mol (≥7.5%), stratified and adjusted for sex, age and data source. Where possible, changes in the proportion of individuals in each HbA1c category compared to previous estimates were calculated.ResultsMedian HbA1c varied from 55 to 79 mmol/mol (7.2 to 9.4%) across data sources and age groups so a pooled estimate was deemed inappropriate. OR (95% CI) for HbA1c< 58 mmol/mol (<7.5%) were 0.91 (0.90–0.92) for women compared to men, 1.68 (1.65–1.71) for people aged <15 years and 0.81 (0.79–0.82) aged15–24 years compared to those aged ≥25 years. Differences between populations persisted after adjusting for sex, age and data source. In general, compared to our previous analysis, the proportion of people with an HbA1c < 58 mmol/l (<7.5%) increased and proportions of people with HbA1c≥ 75 mmol/mol (≥9.0%) decreased.ConclusionsGlycaemic control of type 1 diabetes continues to vary substantially between age groups and data sources. While some improvement over time has been observed, glycaemic control remains sub‐optimal for most people with Type 1 diabetes.
European journal of endocrinology · 2021
Objective Pituitary adenoma (PA) is one of the three major components of multiple endocrine neoplasia type 1 (MEN1). Recent studies have suggested that MEN1-associated PAs are less aggressive than initially estimated. We propose an analysis of the outcome of PAs with a standard of care treatment in a nationwide cohort of MEN1 patients. Design Retrospective observational nationwide cohort study using the MEN1 patient registry from the French Group of Endocrine Tumours (GTE). Methods The GTE database population consists of 1435 patients with MEN1. This analysis focused on 551 patients recruited after 2000 with at least 3 years of follow-up. The study outcome was tumour progression of PA defined by an increase in Hardy classification (HC) during follow-up according to referring physician regular reports. Results Among 551 MEN1 patients (index and related), 202 (36.7%) had PA, with 114 (56.4%) diagnosed by MEN1-related screening. PAs were defined according to HC as microadenoma (grade I) in 117 cases (57.9%), macroadenoma in 59 (29.2%) with 20 HC grade II and 39 HC grades III–IV and unspecified in 26 (12.8%). They were prolactinomas in 92 cases (45.5%) and non-secreting in 73 (36.1%). After a median follow-up of 3 years among the 137 patients with HC grades I–II, 4 patients (2.9%) presented tumour progression. Conclusion PAs in patients with MEN1 are less aggressive than previously thought. Tumour progression is rare with a standard of care monitoring and treatment, especially in related patients who mostly present non-secreting microadenoma. MRI monitoring for asymptomatic MEN1 patients should be reduced accordingly.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Journal of clinical endocrinology and metabolism · 2025 · Journal Article
Humbert L, Proust-Lemoine E, Dubucquoi S, Kemp EH, et al.
Annales d'endocrinologie · 2025 · Journal Article
Raverot G, Chanson P, Delemer B, Drui D, et al.
Annales d'endocrinologie · 2025 · Case Reports
Le Collen L, Charnay T, Ly S, Delemer B, et al.
European journal of endocrinology · 2025 · Journal Article
Le Collen L, Desgrouas C, Lukas Croisier C, Creugnet B, et al.
Journal of diabetes investigation · 2024 · Journal Article
Chibane S, Berot A, Lukas-Croisier C, Dollez L, et al.
Diabetes & metabolism · 2024 · Journal Article
Kouidrat Y, Le Collen L, Vaxillaire M, Dechaume A, et al.
Genetics in medicine : official journal of the American College of Medical Genetics · 2023 · Journal Article
Le Collen L, Delemer B, Poitou C, Vaxillaire M, et al.
The Journal of clinical endocrinology and metabolism · 2022 · Case Reports
Lagarde A, Le Collen L, Boulagnon C, Brixi H, et al.
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022 · Journal Article
Diallo AM, Jaisson S, Barriquand R, Lukas C, et al.
Patient preference and adherence · 2022 · Journal Article
Reach G, Benarbia L, Benhamou PY, Delemer B, et al.
Diabetic medicine : a journal of the British Diabetic Association · 2022 · Journal Article
Prigge R, McKnight JA, Wild SH, Haynes A, et al.
Fertility and sterility · 2022 · Journal Article
Rouen A, Rogers E, Kerlan V, Delemer B, et al.
Abdominal radiology (New York) · 2022 · Journal Article
Lanoix J, Djelouah M, Chocardelle L, Deguelte S, et al.
Annales d'endocrinologie · 2021 · Journal Article
Barraud S, Caron P, Raingeard I, Lefebvre H, et al.
Endocrine · 2021 · Case Reports
Le Collen L, Barraud S, Braconnier A, Coppin L, et al.
The Journal of clinical endocrinology and metabolism · 2025 · Journal Article
Mosbah H, Vatier C, Andriss B, Belalem I, et al.
European journal of endocrinology · 2024 · Journal Article
Mosbah H, Vatier C, Andriss B, Belalem I, et al.
European journal of endocrinology · 2023 · Journal Article
Boukerrouni A, Cuny T, Anjou T, Raingeard I, et al.
Annales d'endocrinologie · 2025 · Journal Article
Vantyghem MC, Nobécourt E, Vatier C, Bismuth E, et al.
European journal of endocrinology · 2023 · Journal Article
Boukerrouni A, Cuny T, Anjou T, Raingeard I, et al.
The British journal of surgery · 2022 · Journal Article
Gaujoux S, Martin GL, Mirallié E, Regenet N, et al.
Pituitary · 2025 · Journal Article
Piazzola C, Le Collen L, Charnay T, Decoudier B, et al.
Medicine · 2022 · Case Reports
Naman A, Delemer B, Marot D, Michelet E, et al.
Annales d'endocrinologie · 2025 · Journal Article
Cuny T, Reynaud R, Raverot G, Coutant R, et al.
Diabetes & metabolism · 2022 · Journal Article
Berot A, Gitton A, Diallo AM, Rahim A, et al.
Annales d'endocrinologie · 2025 · Journal Article
Cuny T, Reynaud R, Raverot G, Coutant R, et al.
Annales d'endocrinologie · 2025 · Consensus Statement
Vantyghem MC, Mirallié E, Al-Salameh A, Aubert S, et al.
Diabetes, obesity & metabolism · 2025 · Journal Article
Lamothe S, Belalem I, Vantyghem MC, Nobecourt E, et al.
JMIR diabetes · 2023 · Journal Article
Nevoret C, Gervaise N, Delemer B, Bekka S, et al.
Diabetes, obesity & metabolism · 2021 · Journal Article
Franc S, Benhamou PY, Borot S, Chaillous L, et al.
Diabetes, obesity & metabolism · 2021 · Journal Article
Franc S, Benhamou PY, Borot S, Chaillous L, et al.
Artificial intelligence in medicine · 2022 · Journal Article
Rabhi S, Blanchard F, Diallo AM, Zeghlache D, et al.
Diabetes, obesity & metabolism · 2025 · Journal Article
Lamothe S, Belalem I, Vantyghem MC, Nobecourt E, et al.
The Journal of clinical endocrinology and metabolism · 2025 · Journal Article
Mosbah H, Vatier C, Andriss B, Belalem I, et al.
GNAS-AS2 supplemental materials
<b>Supplemental figure 1:</b>Panel A : MS-MLPA of 208/II-2: AD-PHP1B patient without <i>STX16</i> deletion.Panel B : MS-MLPA of one AD-PHP1B patient with 3kb <i>STX16</i> deletion (code: 18GP02944). <i>LOM at </i><i>GNAS
Compound genetic etiology in a patient with a syndrome including diabetes, intellectual deficiency and distichiasis
Abstract Background We studied a young woman with atypical diabetes associated with mild intellectual disability, lymphedema distichiasis syndrome (LDS) and polymalformative syndrome including distichiasis. We used diffe
Compound genetic etiology in a patient with a syndrome including diabetes, intellectual deficiency and distichiasis
Abstract Background We studied a young woman with atypical diabetes associated with mild intellectual disability, lymphedema distichiasis syndrome (LDS) and polymalformative syndrome including distichiasis. We used diffe
Evaluation of Nurses’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study
<strong>Article full text</strong> <br><br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text on
GNAS-AS2 supplemental materials
<b>Supplemental figure 1:</b>Panel A : MS-MLPA of 208/II-2: AD-PHP1B patient without <i>STX16</i> deletion.Panel B : MS-MLPA of one AD-PHP1B patient with 3kb <i>STX16</i> deletion (code: 18GP02944). <i>LOM at </i><i>GNAS
Evaluation of Nurses’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study
<strong>Article full text</strong> <br><br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text on
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
European journal of endocrinology · 2022 · Journal Article
Coppin L, Giraud S, Pasmant E, Lagarde A, et al.
Orphanet journal of rare diseases · 2022 · Journal Article
Le Collen L, Delemer B, Spodenkiewicz M, Cornillet Lefebvre P, et al.
European journal of endocrinology · 2021 · Journal Article
Le Bras M, Leclerc H, Rousseau O, Goudet P, et al.